Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 14, 2016; 22(34): 7645-7659
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645
RECIST | mRECIST |
CR: Disappearance of all target lesions. | CR: Disappearance of any intratumoral arterial enhancement in all target lesions. |
PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of the diameters of target lesions. | PR: At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions. |
SD: Any cases that do not qualify for either partial response or progressive disease. | SD: Any cases that do not qualify for either partial response or progressive disease. |
PD: An increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started. | PD: An increase of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started. |
- Citation: Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659
- URL: https://www.wjgnet.com/1007-9327/full/v22/i34/7645.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i34.7645